

## Product Information

# Mucin from bovine submaxillary glands

Type I-S

**M3895**

## Product Description

CAS Registry Number: 84062-64-4

Mucins are highly glycosylated proteins that occur in mucus and the mucous membranes of animals and humans. The principal glycoprotein component of mucus, mucins are associated with such organs as the abdomen and the stomach. Their high degree of glycosylation renders mucins highly stable to digestion in acidic *in vivo* environments such as gastric mucosa.

Olof Hammarsten first isolated bovine submaxillary mucin (BSM) in 1888.<sup>1</sup> The molecular mass of bovine submaxillary mucin has been estimated variously at:

- ~1,600 kDa<sup>2</sup> or ~2,900 kDa<sup>3</sup>, by static light scattering analysis
- ~200-500 kDa, by atomic force microscopy<sup>4</sup>

An earlier publication estimated a molecular mass for the protein backbone of BSM, following acid treatment to remove glycans, in the range of 108-116 kDa.<sup>5</sup>

The protein backbone of BSM is notably rich in Pro, Ser, Thr, and Gly residues.<sup>6</sup> Several molecular biology studies have investigated the sequences in various domains of BSM.<sup>7-9</sup> The thermal stability of BSM in solution has been studied.<sup>10</sup>

In BSM, prevalent glycans include:<sup>7</sup>

- *N,O*-diacetylneuraminic acid
- 2-Acetamido-2-deoxy-D-galactose
- 2-Acetamido-2-deoxy-D-glucose

Fucose and D-Galactose are also present in BSM to lesser degrees.<sup>11</sup> Several publications have probed structural aspects and the isomeric heterogeneity of the carbohydrate groups of BSM, following alkaline borohydride treatment, using various analytical methods such as GC-MS<sup>12</sup> and ion mobility MS.<sup>13</sup>

This non-sterile product is measured for sialic acid content as follows:

- 9-24% (bound)
- ≤2.5% (free)

Several theses<sup>14</sup> and dissertations<sup>15-23</sup> have cited use of product M3895 in their protocols.

## Precautions and Disclaimer

For R&D use only. Not for drug, household, or other uses. Please consult the Safety Data Sheet for information regarding hazards and safe handling practices.

## Storage/Stability

Store the product at -20 °C.

## References

1. Bill, R.M. *et al.*, *Protein Glycosylation*, Chapter 1: "Sugars and Proteins: Getting It Together". Springer Science+Business Media (New York, NY), pp. 1-48 (1998).
2. Shi, L., and Caldwell, K.D., *J. Colloid Interface Sci.*, **224(2)**, 372-381 (2000).
3. Lundin, M. *et al.*, *J. Colloid Interface Sci.*, **336(1)**, 30-39 (2009).
4. Zappone, B. *et al.*, *Langmuir*, **31(15)**, 4524-4533 (2015).
5. Tettamanti, G., and Pigman, W., *Arch. Biochem. Biophys.*, **124(1)**, 41-50 (1968).
6. Bertolini, M. *et al.*, "Glycoproteins: VIII. Glycoproteins Having Many Carbohydrate Groups in Each Protein Unit. A. Epithelial Mucins", in *The Carbohydrates: Chemistry and Biochemistry* (W. Pigman and D. Horton, eds.). Academic Press (New York), pp. 677-684 (1970).

7. Jiang, W. *et al.*, *Biochem. J.*, **331(Pt 1)**, 193-199 (1998).
8. Jiang, W. *et al.*, *Biochem. Biophys. Res. Comm.*, **251(2)**, 550-556 (1998).
9. Jiang, W. *et al.*, *Eur. J. Biochem.*, **267(8)**, 2208-2217 (2000).
10. Madsen, J.B. *et al.*, *J. Colloid Interface Sci.*, **424**, 113-119 (2014).
11. Kim, J. *et al.*, *Biomolecules*, **10(4)**, 636 (2020).
12. Tsuji, T., and Osawa, T., *Carbohydr. Res.*, **151**, 391-402 (1986).
13. Li, H. *et al.*, *Int. J. Mass Spectrom.*, **352**, 9-18 (2013).
14. Hart, Ashley Y., "Effects of resistant starch and soluble fiber on the bioaccessibility of dietary carotenoids from spinach and carrot using simulated *in vitro* digestion". The Ohio State University, M.S. thesis, p. 55 (2012).
15. McCloskey, Natalie, "The Avidity of Human IgG Subclasses". University of London, Ph.D. dissertation, p. 58 (1996).
16. Kamp, Matthias, "Chronische entzündliche Veränderungen der Gallenblasenwand bei Cholezystolithiasis und deren Einfluss auf die Komposition der Blasengalle bei Patienten mit Cholesterin-/ Mischsteinen oder Pigmentsteinen" ("Chronic inflammatory changes in the gallbladder wall in cholecystolithiasis and their influence on the composition of the bladder bile in patients with cholesterol/mixed stones or pigment stones"). Ludwig-Maximilians-Universität zu München, Dr. med. dissertation, p. 27 (2006).
17. Rocha dos Santos, Lívia Joana, "Microbial colonization of contact lenses, tear film deposition, bacterial adhesion and disinfection". Universidade do Minho, Ph.D. dissertation, p. 117 (2008).
18. Lorentz, Holly Irene, "Modeling *In Vitro* Lipid Deposition on Silicone Hydrogel and Conventional Hydrogel Contact Lens Materials". University of Waterloo, Ph.D. dissertation, p. 85 (2011).
19. Ayensu, Isaac, "Development of Novel Formulations for Mucosal Delivery of Protein Based Drugs". University of Greenwich, Ph.D. dissertation, p. 116 (2012).
20. Patil, Navinkumar Jayvant, "Nanomechanics and Nanotribology of Protein Films". University of Calabria, Ph.D. dissertation, p. 100 (2015).
21. Churchward, Colin Peter, "Fatty acids and monoglycerides as novel prophylaxis against gonococcal ophthalmia neonatorum". Kingston University, Ph.D. dissertation, p. 63 (2016).
22. Yarragudi, Sasiu Bhushan, "Formulation Strategies to Enhance Nose-to-Brain Delivery of Drugs". University of Otago, Ph.D. dissertation, p. 33 (2018).
23. Feuerbaum, Stefanie, "Funktionelle Charakterisierung von 9-O-Acetylerasen enterohämorrhagischer *Escherichia coli*" ("Functional characterization of 9-O-acetylerases in enterohemorrhagic *Escherichia coli*"). Universität Hohenheim, Dr. rer. nat. dissertation, p. 31 (2019).

## Notice

We provide information and advice to our customers on application technologies and regulatory matters to the best of our knowledge and ability, but without obligation or liability. Existing laws and regulations are to be observed in all cases by our customers. This also applies in respect to any rights of third parties. Our information and advice do not relieve our customers of their own responsibility for checking the suitability of our products for the envisaged purpose.

The information in this document is subject to change without notice and should not be construed as a commitment by the manufacturing or selling entity, or an affiliate. We assume no responsibility for any errors that may appear in this document.

## Technical Assistance

Visit the tech service page at [SigmaAldrich.com/techservice](https://SigmaAldrich.com/techservice).

## Standard Warranty

The applicable warranty for the products listed in this publication may be found at [SigmaAldrich.com/terms](https://SigmaAldrich.com/terms).

## Contact Information

For the location of the office nearest you, go to [SigmaAldrich.com/offices](https://SigmaAldrich.com/offices).

The life science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.

MilliporeSigma, and Sigma-Aldrich are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.

© 2022 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

M3895pis Rev 05/22 GCY,MAM

**MILLIPORE  
SIGMA**